Keyphrases
Thrombin Generation
100%
Hemophilia
63%
Recombinant Activated Factor VII (rFVIIa)
53%
Emicizumab
40%
Bleeding
26%
Myopic Choroidal Neovascularization (mCNV)
24%
Factor XI Deficiency
21%
FEIBA
20%
Fibrinolysis
19%
Rotational Thromboelastometry (ROTEM)
19%
Hemophilia Patients
19%
Clot Formation
18%
Fibrinogen
18%
Rabbit Model
18%
Hemostasis
18%
Retina
18%
Tissue Plasminogen Activator (t-PA)
17%
Corneal Neovascularization
17%
Rat Model
17%
Glanzmann Thrombasthenia
17%
Activated Protein C
17%
Hemophilia B
16%
Rare Bleeding Disorders
16%
Tissue Factor
15%
Bypassing Agents
14%
Mouse Model
14%
Thrombin Generation Assay
13%
Severe Haemophilia A
13%
Endothelial Cells
13%
Retinal pigment Epithelium
13%
Aflibercept
13%
Thrombin-activatable Fibrinolysis Inhibitor
13%
Riboflavin
13%
Factor VIII (FVIII)
12%
Vascular Endothelial Growth Factor
11%
Bleeding Episodes
11%
Treatment Options
11%
Bleeding Tendency
11%
Bevacizumab
11%
Conjunctival
10%
High-titer Inhibitor
10%
Platelets
10%
Severe Thrombocytopenia
10%
MCF-7
10%
Major Surgery
10%
Murine Model
10%
Inflammation
9%
Replacement Therapy
9%
Retinal Diseases
9%
Thrombosis
9%
Medicine and Dentistry
Thrombin
69%
Haemophilia A
60%
Bleeding
39%
Emicizumab
36%
Haemophilia
31%
Patient with Hemophilia
27%
Factor XI
23%
Recombinant Blood Clotting Factor 7a
20%
Bleeding Disorder
17%
Haemophilia B
17%
Hemostat
17%
Choroidal Neovascularization
17%
Blood Stasis
17%
In Vitro
17%
Factor VII
16%
Activated Prothrombin Complex
15%
Retinal Detachment
13%
Corneal Neovascularization
13%
Riboflavin
13%
Cross-Link
13%
Glanzmann's Thrombasthenia
13%
Activated Protein C
12%
Blood Clotting Factor 8 Inhibitor
12%
Tissue Plasminogen Activator
11%
Blood Clotting
11%
Blood Clotting Factor 8
10%
Substitution Therapy
10%
Vasculotropin
10%
Thromboelastography
10%
Major Surgery
10%
Bleeding Diathesis
9%
Bevacizumab
9%
Thromboelastometry
9%
Pediatrics
9%
Immunological Tolerance
9%
Thrombosis
9%
Endothelial Cell
9%
Ex Vivo
9%
Disease
9%
Retina Disease
9%
Surgical Technique
9%
Platelet
8%
Aflibercept
8%
Histone Deacetylase Inhibitor
8%
Fibrinolysis
8%
NLRP3 Inflammasome
8%
Ciclonicate
7%
Blood Clotting Factor
7%
Proliferative Diabetic Retinopathy
7%
Low Drug Dose
7%
Pharmacology, Toxicology and Pharmaceutical Science
Thrombin
68%
Haemophilia A
48%
Emicizumab
41%
Haemophilia
35%
Bleeding
23%
Blood Clotting Factor 11
23%
Subretinal Neovascularization
23%
Recombinant Blood Clotting Factor 7a
20%
Rat Model
17%
Blood Stasis
16%
Tissue Plasminogen Activator
14%
Activated Prothrombin Complex
14%
Fibrinogen
14%
Bevacizumab
14%
Inflammation
13%
Aflibercept
13%
Cornea Neovascularization
13%
Breast Cancer
13%
Blood Clotting Factor 13
13%
Bleeding Disorder
13%
Activated Protein C
12%
Vasculotropin
12%
Blood Clotting Factor 8
11%
Blood Clotting Factor 7
11%
Blood Clotting Factor 8 Inhibitor
11%
Thromboplastin
10%
Mouse Model
9%
Fibroblast Growth Factor 2
9%
Haemophilia B
9%
Disease
9%
Antifibrinolytic Agent
9%
Hemostatic Agent
9%
Thrombin Activatable Fibrinolysis Inhibitor
8%
Retina Disease
8%
Retina Detachment
8%
Tissue Factor Pathway Inhibitor
7%
Ciclonicate
7%
Proliferative Diabetic Retinopathy
7%
Blood Clotting Factor
7%
Tranexamic Acid
6%
Injury
6%
Antithrombin
6%
Replacement Therapy
5%
Blood Clotting Factor 9
5%
Thrombosis
5%
Rabbit Model
5%
Hypoxia
5%
Thrombocytopenia
5%
Von Willebrand Disease
5%
